Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CSL ( (AU:CSL) ) has provided an announcement.
CSL Limited announced the issuance of 200 ordinary fully paid securities, effective November 5, 2025. This move indicates an ongoing strategy to enhance its capital structure, potentially impacting its market positioning and offering implications for stakeholders regarding the company’s financial strategies.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in plasma therapies, vaccines, and pharmaceuticals, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 1,351,815
Technical Sentiment Signal: Sell
Current Market Cap: A$85.87B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.